Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Hematology. American Society of Hematology. Education Program - 1 Jan 2012

Ghia Paolo

Abstract excerpt

Over the past 2 decades, dramatic improvements in the efficacy of treatments for chronic lymphocytic leukemia have led to progressively higher percentages of clinical complete remissions. A molecular eradication of the leukemia has become not only a desirable, but also an achievable, end point that needs to be evaluated within clinical trials. The assessment of complete remission only at the clinical and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Flow Cytometry

Share to Immunotherapy

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Neoplasm, Residual

Share to Recurrence

Share to Remission Induction

Source

Identifiers

PMID: 23233566
DOI: 10.1182/asheducation-2012.1.97

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?PMID 23233566Read ↗

Minimal residual disease assessment in chronic lymphocytic leukaemia.Semantic proximity Read ↗

Detection of minimal residual disease in leukemias: a critical approach.Semantic proximity Read ↗

Minimal residual disease in acute myeloid leukemia: coming of age.Semantic proximity Read ↗

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesSemantic proximity Read ↗

Should minimal residual disease guide therapy in AML?Semantic proximity Read ↗

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Semantic proximity Read ↗

Detection and management of minimal residual disease in acute lymphoblastic leukemiaSemantic proximity Read ↗

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.Semantic proximity Read ↗

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaSemantic proximity Read ↗

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic LeukemiaSemantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Detection of minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.